A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Summary

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then attack the tumor cells in people with solid tumors. ASP2998 will either be given by itself, or given together with one or more of standard cancer treatments pembrolizumab, carboplatin, and enfortumab vedotin. This is an early development study to collect information about ASP2998 in people with solid tumors. In this study ASP2998 will be given to humans for the first time.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Locally Advanced or Metastatic Malignant Solid Tumors

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Astellas Pharma Global Development, Inc.

Last updated on ClinicalTrials.gov

September 2, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites